Physician profile
Bruce A Aronwald
NPI 1154375467
$2,061.54
in general payments reported to CMS, 2019-2025
25 companies · $371 in 2025
The $371 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $37.22 · 2021: $206 · 2022: $356 · 2023: $233 · 2024: $481 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,084.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $413.06 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $376.62 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $291.73 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $170.81 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $104.58 | 2022-2025 | |
| Lilly USA, LLC | $104.16 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $94.81 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $92.33 | 2019-2022 | |
| Azurity Pharmaceuticals, INC. | $59.20 | 2023-2024 | Edarbyclor, Edarbi |
| Bausch Health US, LLC | $41.54 | 2020-2022 | |
| Exact Sciences Corporation | $40.63 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $39.62 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $32.55 | 2024-2025 | Contrave |
| Kowa Pharmaceuticals America, INC. | $27.18 | 2021-2022 | |
| Horizon Therapeutics Plc | $24.17 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $22.74 | 2025 | Freestyle Libre 3 |
| Ani Pharmaceuticals, INC. | $15.92 | 2024 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $15.06 | 2024 | Arexvy |
| Althera Pharmaceuticals LLC | $14.57 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.48 | 2019 | |
| Almatica Pharma LLC | $13.94 | 2023 | Gralise, Loreev Xr |
| Idorsia Pharmaceuticals US INC | $13.34 | 2023 | Quviviq |
| Alfasigma USA, INC. | $13.26 | 2022 | |
| Ironshore Pharmaceuticals INC. | $13.18 | 2019 | |
| Kaleo, INC. | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Aronwald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.